Phenotype
The subject was born prematurely of a non-consanguineous mating at 36 weeks gestation weighing 1.56 kg and measuring 42 cm long (3 rd percentile). At birth the subject presented with bilateral radial aplasia and absent thumbs, microcephaly, micrognathia, café au lait spots, small ventricular septal defect (VSD) and patent ductus arteriosus (PDA), and absent left kidney. At birth the subject had thrombocytopenia that resolved in subsequent days. The subject has history of normal Adrenocorticotropic hormone (ACTH) and Growth Hormone (GH) stimulation. The subject takes thyroid replacement therapy for hypothyroidism. Cardiac evaluation by ECG was normal and echocardiogram reveals a normal heart with normal valve anatomy and function. The subject has a solitary right kidney and normal renal function with a creatinine of 0.57. Currently, the subject is 16 years of age, performs well in school with no known learning disabilities, and is generally active. The subject has bilateral conductive hearing loss and uses hearing aids. The subject's height remains below the 5 th percentile and most recent bone age was slightly greater than chronological age (17y/o).
Family History
Thalassemia, no history of early onset cancer or bone marrow failure Clinical Chromosomal Breakage Analysis Cytogenetic studies were performed at The Rockefeller University on several peripheral blood (PB) samples over the years. Initially breakage levels of PB collected at 2 days old was significantly elevated at 5.8 breaks per cell in 85% of the cell population. Decreasing breakage levels over time demonstrate the development of somatic mosaicism (see Table S2 ).
Hematological Status
Annually the subject is seen at Cincinnati Children's hospital for bone marrow testing. Most recent blood counts report a hemoglobin of 13.9, platelet count of 202,000, and white blood cell count of 6.6 (absolute neutrophil count mildly decreased at 0.79 and an elevated absolute lymphocyte count of 5.6). Peripheral blood smear shows moderate neutropenia and microcytic red blood cells consistent with thalassemia trait. Bone marrow aspirate is mildly hypocellular with trilineage hematopoiesis. Marrow biopsy demonstrates mildly hypocellular marrow for age in the 35-45% range with trilineage hematopoiesis. Chromosome studies show a normal karyotype. No evidence of abnormal clonal cells, MDS, or leukemia. Figure 3 . Table S2 . Chromosome breakage analysis of subject's peripheral blood samples treated with DEB. Related to Figure 1 .
Extended Experimental Procedures

Cell culture and viral transfection/transduction
Proband fibroblasts (RA2627), FANCA deficient fibroblasts (RA3087) non-FA control fibroblasts (RA3380) and BJ foreskin normal control fibroblasts (ATCC) were transformed by expression of HPV16 E6E7 and immortalized with the catalytic subunit of human telomerase (hTERT). (Kim et al., 2013) .
Plasmids
UBE2T cDNA was obtained from the Human ORFeome V8.1 Library (GE Healthcare), cloned into pDONR223 and recombined with a pMSCV retroviral vector using Gateway system (Invitrogen), resulting in a C-terminally HA-FLAG tagged UBE2T.
Cell cycle, chromosomal breakage, and cell survival analyses
Analysis of cell cycle and chromosomal breakage following treatment with DNA damaging agents was performed as described (Kim et al., 2011) . For cell survival assays, cells were seeded overnight and treated next day with DNA damaging agents at indicated concentrations. Cells were grown for 3-4 days and passaged once at appropriate ratios. Once cells reached near confluence, cells were counted using Z2 Coulter counter (Beckman Coulter).
In the case of cisplatin treatment, drug was removed after 1hr and cells were washed with PBS and given fresh drug-free media.
aCGH
A custom CGH array was designed as previously described (Chandrasekharappa et al., 2013) . NimbleGen Service for CGH was used for manufacturing, hybridization, scanning, and preliminary analysis. DNA from the proband was compared to reference human male DNA (Promega). Data analysis was performed using NimbleScan and intensity variations were visualized using SignalMap (NimbleGen software).
Whole Exome Sequencing
For proband and one parent, libraries for whole exome sequencing (WES) were constructed and sequenced on Illumina HiSeq 2000 or Illumina GA-IIX using 76 bp paired-end reads at the Broad Institute. For the second parent exome capture was performed using Agilent SureSelect Human All Exon V4 capture kit and 100 bp paired-end sequencing was done on Illumina HiSeq 2500. Sequence was aligned to human genome build GRCh37 using BWA (Burrows-Wheeler Aligner) (Li and Durbin, 2009) . Duplicate reads were marked using Picard [http://picard.sourceforge.net]. Genome Analysis Toolkit (GATK) was used for base quality score recalibration (BQSR), and local realignment around indels . Variant discovery was performed in part by variant calling with GATK HaplotypeCaller and then joint genotyping with GATK GenotypeGVCFs. The variant call set was then refined with Variant Quality Score Recalibration (VQSR) and VQSR scores helped discriminate low quality variants.
Variant annotation was performed using SnpEff, VCFtools, and in-house software (NYGC) (Cingolani et al., 2012; Danecek et al., 2011) . All three subjects were analyzed with the NYGC sequence analysis pipeline.
PCR, reverse transcription, and RT quantitative PCR
PCR reactions were performed using Taq DNA Polymerase (Qiagen), Phusion HighFidelity PCR Master Mix with GC buffer (Thermo Scientific), and PCR SuperMix High Fidelity (Invitrogen) according to manufacturer's protocols and primers are listed in Table S4 . Total messenger RNA was extracted using RNeasy plus kit (Qiagen). Superscript III reverse transcriptase followed by Platinum SYBR Green SuperMix-UDG (Invitrogen) was used according to manufacturer's protocol and normalized against GAPDH.
Detailed analysis of biallelic UBE2T mutations in proband
Sanger sequencing of genomic DNA and cDNA from proband primary fibroblasts (RA2627) and parental peripheral blood and lymphoblast cells was performed to identify compound heterozygous mutations. The paternally derived deletion was identified by genomic sequencing of the proband and parental DNA. Genomic deletion was suspected based on inheritance of informative polymorphic marker rs14451 (exon 2) detected in whole exome sequencing of the proband and parental DNA. PCR and Sanger sequencing of the UBE2T locus confirmed this finding and revealed additional informative markers rs10753914 (IVS1) and rs788801 (IVS6). Genomic PCR using primers flanking these markers and Sanger sequencing confirmed the presence of the g.202332626_202341295del mutation in the proband and father ( Figure S1A-C) . The ~8.7kb sequence intervening the IVS1 AluYa5 and IVS6 AluYa5 repeats is lost in the paternal allele in the proband which was further confirmed by cloning of the genomic PCR products.
The maternally inherited mutation was identified by a detailed analysis of the RA2627 cDNA. Amplification of parts of the cDNA and sequence analysis revealed a unique exon 6-exon 2 junction, suggesting a genomic duplication of a region of UBE2T. This unique junction was also found in the genomic DNA from the proband and mother using PCR and Sanger sequencing. The region following exon 6 was found to contain IVS6 sequence flanking the 5' of the AluYa5 repeat and IVS1 sequence flanking the 3' of the repeat, and was confirmed by cloning ( Figure S2A,B) . To confirm the extent of the duplication, genomic analysis of the duplicated exon 6 and intronic region was investigated in the proband and parental genomic samples. The predicted sequence, exon6-IVS6-exon7, was identified by PCR and Sanger sequencing and was further confirmed by cloning of the single genomic PCR product. ( Figure   S2C ). Cloning of the RA2627 full-length cDNA (5'UTR in exon 1 through 3' UTR exon 7) revealed a low frequency cDNA transcript containing the hypothesized duplication, c.-64_468dup (dupEx2_6), (Figure SD,E) . The genomic and transcript analysis indicate that the maternally derived duplication is g.202332626_202341295dup.
